Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ondine BiomedicalFRA:VF5 37 Debt-to-Equity is 0.12 as of Dec. 2025, which is 500% above its 10-year median of 0.02. GuruFocus rates FRA:VF5 with a GF Score™ of 37/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 970 Biotechnology companies, Ondine Biomedical ranks better than 55.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ondine Biomedical's Debt-to-Equity or its related term are showing as below:
FRA:VF5'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.65 Med: 0.02 Max: 0.26
Current: 0.12
During the past 13 years, the highest Debt-to-Equity Ratio of Ondine Biomedical was 0.26. The lowest was -1.65. And the median was 0.02.
FRA:VF5's Debt-to-Equity is ranked better than 55.88% of 970
companies
in the Biotechnology industry
Industry Median: 0.15
vs FRA:VF5: 0.12
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ondine Biomedical Debt-to-Equity Related Terms
Ondine Biomedical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VF5 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Ondine Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ondine Biomedical (FRA:VF5) has a Debt-to-Equity of 0.12 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ondine Biomedical and its competitors. This is 500% above median its historical median of 0.02. According to the industry distribution chart, Ondine Biomedical ranks #428 out of 970 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Ondine Biomedical's Debt-to-Equity too high?
Ondine Biomedical's current Debt-to-Equity of 0.12 is 500% above median its 10-year median of 0.02. The Biotechnology industry median Debt-to-Equity is 0.15. Ondine Biomedical's value of 0.12 is 20% below this industry median. Based on the distribution chart, Ondine Biomedical ranks #428 out of 970 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ondine Biomedical has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #428 out of 970 companies for Debt-to-Equity. This puts Ondine Biomedical in the upper half of its industry. The industry median Debt-to-Equity is 0.15. Ondine Biomedical's value of 0.12 is 20% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.15, Ondine Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ondine Biomedical's current Debt-to-Equity of 0.12 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ondine Biomedical and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ondine Biomedical's current Debt-to-Equity is 0.12, which is 500% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.14 — trading 54.4% above its estimated fair value. The current Debt-to-Equity is 0.12, which is 500% above median its 10-year median of 0.02 and 20% below the Biotechnology industry median of 0.15. Ondine Biomedical's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current Debt-to-Equity is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of €0.14 is trading 54.4% above its estimated GF Value™ of €0.09.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for FRA:VF5:
Debt-to-Equity: 0.12 (500% above median its 10-year median of 0.02)
GF Value™: €0.09 vs. price of €0.14 (54.4% above fair value)
Industry Position: 20% below the Biotechnology median (#428 of 970)
No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
37GF Score
Get the complete analysis for FRA:VF5
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
